SciSparc Secures Highly Dilutive $10M Convertible Note and Warrant Financing

summarizeSummary

SciSparc Ltd. secured up to $10 million in highly dilutive convertible notes and warrants, with an initial $2.5 million note issued at a discount, signaling significant financial strain and potential for substantial shareholder dilution.

check_boxKey Events

• Secures Up to $10M in Convertible Notes

  SciSparc Ltd. entered a Securities Purchase Agreement for convertible promissory notes totaling up to $10 million in principal, with an initial $2.5 million note issued at a 10% discount.

• Highly Dilutive Terms

  The financing includes 100% warrant coverage and a variable conversion price for the notes (88% of lowest VWAP, with a low floor price), alongside warrants exercisable below the current stock price, indicating substantial future dilution.

• Non-Recourse Debt Structure

  The convertible notes are non-recourse, with the exercise of accompanying warrants serving as the sole remedy for non-payment, a highly unusual and unfavorable term for the company.

• Follows Recent Dilutive Offerings

  This financing follows a universal shelf registration for up to $50 million filed on February 3, 2026, and a registered direct offering on January 14, 2026, continuing a trend of significant capital raises.

auto_awesomeAnalysis

SciSparc Ltd. has entered into a Securities Purchase Agreement for up to $10 million in convertible promissory notes and accompanying warrants. The initial note, with a principal of $2.5 million, was issued at a 10% discount for $2.25 million. The terms are highly dilutive, featuring 100% warrant coverage and a variable conversion price for the notes (88% of lowest VWAP, with a low floor price), alongside warrants exercisable below the current stock price. This financing structure, often termed "death spiral" financing, indicates significant financial distress and will result in substantial dilution for existing shareholders if fully utilized. The non-recourse nature of the notes, with warrant exercise as the sole remedy for non-payment, further underscores the unfavorable terms for the company. This follows a pattern of dilutive offerings, including a $50 million shelf registration and a recent registered direct offering, and is being executed while the stock trades near its 52-week lows.